Strontium is a mineral used as the prescription salt ranelate (withdrawn) and as dietary supplements such as citrate for fracture prevention in fragile bone. In older women with osteoporosis, ranelate was tied to fewer spine fractures and fewer other fractures. Clots were more common and the heart-attack picture is unsettled. Supplement salts lack a fracture trial. Density scans include an X-ray artifact. This concerns fractures and mobility, not slowing aging. (Full Review)
| Marker | Target | Why |
|---|---|---|
| DXA, lumbar spine and hip | No established target on strontium; track percent change from the person's own baseline | Shows whether the reading is moving, including artifact |
| 25-hydroxyvitamin D | 40–60 ng/mL | Background for the mineral effect seen in trials |
| Serum calcium | 9.0–10.0 mg/dL, mid-normal | Detects calcium imbalance while strontium is used |
| Creatinine clearance or eGFR | At or above 90 mL/min | Strontium is renally cleared |
| CTX | No fixed target; a fall from the person's baseline is the signal used in trials | Resorption context |
| P1NP | No fixed target; direction versus the person's baseline | Formation context |
Cadence: Baseline DXA, serum calcium, kidney filtration, 25-hydroxyvitamin D, blood pressure, and history of heart disease, stroke, or clots. DXA at about 12 months, then every 12–24 months. Kidney filtration and calcium at about 3 months, then yearly. Turnover markers yearly if used. Earlier review for a new rash with fever, one-sided leg swelling, or chest pain.